Abstract
Myocyte enhancer factor-2 (MEF2), a family of transcription factors originally identified in muscles cells, was recently found to be expressed in the central nervous system. It is involved in the modulation of synapse elimination, a vital process that determines the fate and function of neurons. Recent studies suggested that MEF2 transcription factors are involved in synaptic plasticity, the molecular mechanism underlying learning and memory and other processes involved in dementia and neurodegenerative disease. This review summarizes recent advancements in understanding the role of MEF2 in neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease, and Fragile X syndrome.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
